Vismodegib (GDC-0449)

For research use only. Not for use in humans.

目录号：S1082 中文名称：维莫德吉

Vismodegib (GDC-0449) Chemical Structure

CAS No. 879085-55-9

Vismodegib (GDC-0449)是一种新型有效的，特异性hedgehog抑制剂，无细胞试验中IC50为3 nM，也会抑制P-gp，IC50为3.0μM。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1179.52	现货
5mg	RMB 730.63	现货
50mg	RMB 3046.91	现货
200mg	RMB 8763.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vismodegib (GDC-0449)发表文献144篇：

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Nat Med, 2018, 24(3):271-281

PubMed: 29400712 ( click the link to review the publication )

Nat Med, 2017, 23(10):1191-1202

PubMed: 28892064 ( click the link to review the publication )

Nature, 2016, 535(7613):517-22

PubMed: 27437577 ( click the link to review the publication )

Nature, 2014, 3;511(7507):90-3.

PubMed: 24870236 ( click the link to review the publication )

Nat Med, 2014, 20(9):1035-42

PubMed: 25150496 ( click the link to review the publication )

Nat Med, 2014, 20(7):732-40

PubMed: 24973920 ( click the link to review the publication )

Cancer Cell, 2014, 26(1):33-47

PubMed: 24954133 ( click the link to review the publication )

Gastroenterology, 2012, 143(5):1319-29.e1-11

PubMed: 22885334 ( click the link to review the publication )

Genes (Basel), 2021, 12(1)E120

PubMed: 33477943 ( click the link to review the publication )

Cell Death Dis, 2021, 12(2):199

PubMed: 33608498 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5079

PubMed: 33033234 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(18):10342-10352

PubMed: 32894284 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Theranostics, 2020, 10(4):1719-1732

PubMed: 32042332 ( click the link to review the publication )

Cancer Res, 2020, 5 pii: canres

PubMed: 32371475 ( click the link to review the publication )

Cells, 2020, 10(1)E53

PubMed: 33396427 ( click the link to review the publication )

Aging (Albany NY), 2020, 10.18632/aging.103230

PubMed: 32544883 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Front Oncol, 2020, 10:563838

PubMed: 33312948 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00514-2

PubMed: 32958873 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

PLoS One, 2020, 29;15(4):e0231762

PubMed: 32348319 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Oncotarget, 2020, 11(33):3174-3187

PubMed: 32913560 ( click the link to review the publication )

JCI Insight, 2020,

PubMed: 32814713 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13400

PubMed: 32770014 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5151-5162

PubMed: 31638600 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(7):1439-1448

PubMed: 30707899 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31601026 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):952

PubMed: 31844040 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 10.1530/ERC-18-0538

PubMed: 30645190 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):364

PubMed: 31791391 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0346-2

PubMed: 31758086 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19623

PubMed: 31873117 ( click the link to review the publication )

Sci Rep, 2019, 9(1):3353

PubMed: 30833624 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

J Biol Chem, 2019, 294(9):3284-3293

PubMed: 30573683 ( click the link to review the publication )

J Biol Chem, 2019, 294(25):9787-9798

PubMed: 30992365 ( click the link to review the publication )

Front Pharmacol, 2019, 10:89

PubMed: 30846937 ( click the link to review the publication )
Front Genet, 2019,

PubMed: 31867038 ( click the link to review the publication )

Toxicol Lett, 2019, 313:30-41

PubMed: 31181250 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):437-446

PubMed: 30365081 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0226570

PubMed: 31860685 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Int J Oral Sci, 2019, 11(1):3

PubMed: 30783111 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(8):909-916

PubMed: 30038251 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2897

PubMed: 30042390 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Sci Signal, 2018, 11(547)eaau5147

PubMed: 30206138 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(4):357-369

PubMed: 29396292 ( click the link to review the publication )

Oncoimmunology, 2018, 8(3):1548241

PubMed: 30723576 ( click the link to review the publication )

Eur J Med Chem, 2018, 156:554-562

PubMed: 30025349 ( click the link to review the publication )

Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Bone Res, 2018, 6:30

PubMed: 30345151 ( click the link to review the publication )

Cancer Res, 2017, 77(12):3217-3230

PubMed: 28515149 ( click the link to review the publication )

J Control Release, 2017, 261:105-112

PubMed: 28662901 ( click the link to review the publication )

Oncogene, 2017, 36(32):4641-4652

PubMed: 28368412 ( click the link to review the publication )

Oncogene, 2017, 36(45):6306-6314

PubMed: 28714964 ( click the link to review the publication )

Br J Cancer, 2017, 117(9):1314-1325

PubMed: 28881358 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3815

PubMed: 28630423 ( click the link to review the publication )
Sci Rep, 2017, 7(1):13379

PubMed: 29042665 ( click the link to review the publication )

Am J Pathol, 2017, 187(5):1068-1092

PubMed: 28315313 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2017, 79(2):411-420

PubMed: 28110457 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1106-1117

PubMed: 28799948 ( click the link to review the publication )

J Craniofac Surg, 2017, 28(6):1607-1614

PubMed: 28863112 ( click the link to review the publication )

Oncotarget, 2017, 8(47):82123-82143

PubMed: 29137250 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103744-103757

PubMed: 29262597 ( click the link to review the publication )

Cell Cycle, 2017, 16(14):1357-1365

PubMed: 28562206 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(2):214-222

PubMed: 26189371 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371980 ( click the link to review the publication )

Oncotarget, 2017, 8(30):48660-48670

PubMed: 27750213 ( click the link to review the publication )

Hepatology, 2016, 63(4):1155-69

PubMed: 26473743 ( click the link to review the publication )

NATURE COMMUNICATIONS, 2016, 10.1038/ncomms10993

PubMed: 27001906 ( click the link to review the publication )

Nat Commun, 2016, 7:11151

PubMed: 27039827 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )

Cancer Res, 2016, 76(18):5538-49

PubMed: 27488530 ( click the link to review the publication )

Arthritis Rheumatol, 2016, 68(10):2432-43

PubMed: 27159076 ( click the link to review the publication )

Cell Death Dis, 2016, 7(9):e2376

PubMed: 27899820 ( click the link to review the publication )

Stem Cells, 2016, 34(1):55-66

PubMed: 26418365 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:9826726

PubMed: 27143997 ( click the link to review the publication )

Sci Rep, 2016, 6:22540

PubMed: 26931153 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):301-8

PubMed: 26762562 ( click the link to review the publication )

Mol Med Rep, 2016, 13(2):1434-40

PubMed: 26676867 ( click the link to review the publication )
Oncotarget, 2016,

PubMed: 26936993 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4686-97

PubMed: 26124204 ( click the link to review the publication )

PLoS Genet, 2015, 11(6):e1005214

PubMed: 26091072 ( click the link to review the publication )

Development, 2015, 142(19):3374-82

PubMed: 26293299 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Sci Rep, 2015, 5:14135

PubMed: 26370741 ( click the link to review the publication )

Sci Rep, 2015, 5:16232

PubMed: 26549569 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Breast Cancer Res Treat, 2015,

PubMed: 25904215 ( click the link to review the publication )

Cell Cycle, 2015, 747:71-87

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(1):31-45

PubMed: 25496115 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0116390

PubMed: 25775002 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0139830

PubMed: 26439749 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 457(3):318-23

PubMed: ( click the link to review the publication )

Oncol Lett, 2015, 9(6):2675-2679

PubMed: 26137127 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28895-910

PubMed: 26336820 ( click the link to review the publication )

Sci Rep, 2015, 5:7915

PubMed: 25604826 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1405-18

PubMed: 25176648 ( click the link to review the publication )

J Exp Clin Cancer Res, 2014, 33:34

PubMed: 24758269 ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(8):2684-98

PubMed: 24682719 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2014, 21(8):2684-98

PubMed: 24450438 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )
Universite Pierre et Marie Curie , 2014, LEPRIEUR EP

PubMed: ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Gut, 2013, 62(2):299-309

PubMed: 22362915 ( click the link to review the publication )

Hepatology, 2013, 58(4):1362-74

PubMed: 23703673 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Thyroid, 2013, 23(9):1119-26

PubMed: 23410206 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):74-83

PubMed: 23111106 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 147(1):508-16

PubMed: 24094913 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1805-12

PubMed: 23868912 ( click the link to review the publication )

PLoS One, 2013, 8(6):e65032

PubMed: 23762282 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74141

PubMed: 24066108 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Hematology, 2013, 88(4):265-72

PubMed: 23475625 ( click the link to review the publication )

Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Gut, 2012, 61(9):1323-9

PubMed: 22427237 ( click the link to review the publication )

Cancer Res, 2012, 72(22):5912-20

PubMed: 22986746 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(6):1040-8

PubMed: 22554036 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Chem Biol, 2012, 19(8):972-82

PubMed: 22921064 ( click the link to review the publication )

Hepatology, 2011, 54(5):1580-90

PubMed: 21793033 ( click the link to review the publication )

Mol Cancer, 2011, 10:66

PubMed: 21619683 ( click the link to review the publication )

PLoS One, 2011, 6(9):e23943

PubMed: 21912653 ( click the link to review the publication )

J Neurooncol, 2011, 105(3):475-83

PubMed: 21633906 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Vismodegib (GDC-0449)是一种新型有效的，特异性hedgehog抑制剂，无细胞试验中IC50为3 nM，也会抑制P-gp，IC50为3.0μM。

靶点

Hedgehog ^[1]
(Cell-free assay)

3 nM

体外研究

GDC-0449有效抑制hedgehog通路，是一种新型及特定合成的小分子抑制剂，IC50为3nM。^[1] GDC-0449作用于Hedgehog信号通路，阻断Hedgehog配位体，即细胞表面受体PTCH 及SMO的活性，从而阻断Hedgehog信号通路。在组织生长和修复方面，Hedgehog信号通路意义重大。Hedgehog通路信号的异常激活，及不受控制的细胞增殖，可能与Hedgehog配位体，即细胞表面受体PTCH 及SMO的突变有关。在体外，GDC-0449在不抑制胰脏细胞增殖的前提下阻止原代胰脏移植物的生长，这项结果最近已经应用到临床。GDC-0449也抑制ABCG2, P-糖蛋白, 及和MDR有关联的重要MRP1 ABC载体。GDC-0449也阻断其他多种ABC载体。ABC载体属于一个膜蛋白家族，它的过量表达和耐药性有关，这也是治疗癌症的一个重大障碍。GDC-0449强抑制两种ABC载体，ABCG2/BCRP和ABCB1/P-糖蛋白，也温和抑制ABCC1/MRP1。在ABCG2过量表达的HEK293细胞中, GDC-0449可以提高荧光ABCG2底物BODIPY-哌唑嗪的保持力，也可用米托蒽醌再次处理这些细胞，产生抗肿瘤的ABCG2底物。实验使Madin-Darby犬的肾脏细胞中过量表达P糖蛋白或者MRP1，GDC-0449 提高了钙黄绿素-AM的保持力，然后载用秋水仙素处理这些细胞。另外，用米托蒽醌,托泊替康,SN-38处理的过量表达ABCG2的人类非小细胞肺癌细胞NCI-H460/par和NCI-H460/MX20，用GDC-0449再次处理。GDC-0449 作用于ABCG2 和 Pgp 的IC50值分别为1.4μM和 3.0 μM。^[2]GDC-0449 改变细胞内Ca²⁺ 平衡，且作用于抗cisplatin的肺癌细胞，抑制细胞生长。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
IGROV-1	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MofhTWM2OD1yLkC3NlQ5KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
HCE-T	M{XNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWPJR\|UxRTFwM{KyOFch\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
D-542MG	NGHsZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlrDTWM2OD1zLki2O\|M4KM7:TR?=	NV72WolzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
23132-87	NV;lSWRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mm\jTWM2OD12LkSwNVQ4KM7:TR?=	NWS4fG51RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
HDLM-2	NYrF[lJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFjkOI9KSzVyPUiuNFQ4PjZizszN	NHW0Tnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
ACN	NFvFbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXyzblAyUUN3ME24MlUxOTB7IN88US=>	M1XmPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HuO-3N1	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{[3bmlEPTB;OT62NFExQCEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
BHT-101	NEexPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmD1TWM2OD1zMT6zPEDPxE1?	NYnsNJhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
KYSE-150	M3n2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MW\JR\|UxRTFzLkW4OFEh\|ryP	NUP4VGxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
MC-IXC	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV75RYR7UUN3ME2xNk4zOjl{IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
D-423MG	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXixdGc3UUN3ME2xNk44PjV5IN88US=>	MlrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NY	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MULJR\|UxRTF2Lki5NFMh\|ryP	NHrqVGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
HOS	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEDMS3hKSzVyPUG1MlY4OTlizszN	NUXoW4RpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
NB7	M1Sxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH\xb3ZKSzVyPUG1Mlg6OSEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
DMS-273	M4H3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1LUZWlEPTB;MU[uOlcyOyEQvF2=	M3vuUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
MDA-MB-361	NX7IOlhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{[1UWlEPTB;MUeuNlcyOSEQvF2=	NGrWV209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
DU-145	MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M37KNWlEPTB;MUiuN\|Ih\|ryP	NGrJR5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
NCI-H82	NFvDS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWXJR\|UxRTF7LkizPFYh\|ryP	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	M{nGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUTJR\|UxRTJyLkCxPVYh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
GCT	NY\wS21TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV\JR\|UxRTJyLki4NlQh\|ryP	M2HkUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
C2BBe1	M3\Pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWXJR\|UxRTJzLkGwOVgh\|ryP	NFWxNo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
LB2241-RCC	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2PBOGlEPTB;MkGuPFQ1OSEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
COLO-829	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3S3b2lEPTB;MkKuNVg4OSEQvF2=	NH7DR4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
EW-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnfaTWM2OD1{Mj64NFIzKM7:TR?=	NX20WJZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
NCI-H526	NEfEcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoHkTWM2OD1{Mz60O\|E4KM7:TR?=	NIO2N2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
SF295	Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUDT[XE2UUN3ME2yOE4xOjV{IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
D-566MG	NIrFT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUHBWmJEUUN3ME2yOU4zQTR\|IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
8505C	NVjWdJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1nQe2lEPTB;MkWuOlM{OSEQvF2=	M1i3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HT-29	NFr3dHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3\KfmlEPTB;Mk[uNFQ{OSEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
NBsusSR	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3v5[2lEPTB;Mk[uPFAxPiEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
BV-173	NH3HepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnnUTWM2OD1{OD6zNVgzKM7:TR?=	M37US\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CTB-1	NFTrTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlXZTWM2OD1\|MD6xNFMyKM7:TR?=	NYiySokzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
JAR	NF\jdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIT4NJlKSzVyPUOyMlU{PzFizszN	M3HYWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CAMA-1	NYLt[o02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MknmTWM2OD1\|Mz60OlE2KM7:TR?=	MkLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
CAL-51	NU\oWFl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH;aRnRKSzVyPUO0MlcyPzZizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
A172	NWjFVnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{nFSWlEPTB;M{euOFkzOSEQvF2=	NHvpVJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
QIMR-WIL	NXrpbJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYTDVZFWUUN3ME2zPE4xPzB6IN88US=>	MkWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
AsPC-1	NVS3c\|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2fzcWlEPTB;M{iuOFY2OSEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
MKN7	NICydpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkLmTWM2OD1\|OT6wNFc6KM7:TR?=	MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
ONS-76	NV;GVWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFux[4ZKSzVyPUSzMlMxPTdizszN	NIjj[Ww9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
RS4-11	M{DEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnuwTWM2OD12ND6wO\|UzKM7:TR?=	MnnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NOS-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF\WWlRKSzVyPUS0MlYxOzFizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
A101D	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXzJR\|UxRTR2LkiwNlMh\|ryP	MojyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
HCC1806	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2PaVGlEPTB;NE[uNVE1QCEQvF2=	M3XHb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CAL-27	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHJR\|UxRTR5LkeyOFYh\|ryP	M4C4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
BT-549	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGX1WpBKSzVyPUS4MlU{OTVizszN	NW\jN2d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVLZUnUzUUN3ME20PU4zPDF\|IN88US=>	NHHKSmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
A4-Fuk	M4fWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXnqcoNwUUN3ME20PU45PDlizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
OVCAR-4	M{HvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkLmTWM2OD13MD6wOlAyKM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
HD-MY-Z	NXXtUGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUHJR\|UxRTVyLke3OlQh\|ryP	NW\iRW5GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
NCI-H292	M2n6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXzndFg3UUN3ME21NE45PzV6IN88US=>	M2PH[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
Sk-ChA-1	NYXGVpFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVKwMlI26oDVNUCg{txO	M2nXNlczKGh?	MmC1TWM2OD15ND61OOKyOi53ON88US=>	NFL1O4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0NlQ5Oid-MkW3OFI1QDJ:L3G+
Mz-ChA-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnm1NE4zPeLCk{WwJO69VQ>?	NHXISVQ4OiCq	NEXEcm1KSzVyPUW0Mlk4yrF\|LkS1{txO	NF;uTIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0NlQ5Oid-MkW3OFI1QDJ:L3G+
Smo-WT	NVzaU\|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX:1OXBxUUN3MNMgc4YhOTUEoH7N	M3q1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkmxNVA1Lz5{NEK5NVExPDxxYU6=
Smo-D473H	NHn0[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH;lN\|NKSzVywrDv[kA4NjIEoN88US=>	M{n6O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkmxNVA1Lz5{NEK5NVExPDxxYU6=
K562	Mkn4SpVv[3Srb36gRZN{[Xl?	MWCxNEDPxE1?	M1H4PFczKGh?	NYD3XpR1emWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBIdGlzwrC=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzOUiyOEc,OjN\|MUm4NlQ9N2F-
T315I BCR-ABL BaF3	M1O5O2Z2dmO2aX;uJGF{e2G7	MoDXNVAh\|ryP	MnfCO\|IhcA>?	MnTjdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDHcIkyyqB?	MnfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUm4NlQoRjJ\|M{G5PFI1RC:jPh?=
TF-1 BCR-ABL	Mnq5SpVv[3Srb36gRZN{[Xl?	MVyxNEDPxE1?	NULWUIxiPzJiaB?=	Mon4doVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDHcIkyyqB?	NUTjWVFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVk5OjRpPkKzN\|E6QDJ2PD;hQi=>
Shh-Light 2	NULxU2FbTnWwY4Tpc44h[XO\|YYm=		Ml7FNkBl[Xm\|	Ml;URY51[WexbnnzeEBi[3Srdnn0fUBifCCVbX:gbY4hdW:3c3WgV4hpNUyrZ3j0JFIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTbIgucW6mdXPl[EBIdGlzLYLldI9zfGW{IHHjeIl3cXS7IHHmeIVzKDJiZHH5d{BjgSCmdXHsMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDt[ZRpd2RuIFnDOVAhRSByLkCwNVUh\|ryPLh?=	Mkm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
NIH/3T3	M3HD[WZ2dmO2aX;uJIF{e2G7			MVTJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIJ6KEeuaT3keYFtNWy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUCgQUAxNjByMkOg{txONg>?	M4n5TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUiwNFEzLz5{N{G4NFAyOjxxYU6=
NIH/3T3 Light2	Mmf3SpVv[3Srb36gZZN{[Xl?			NFf1[I9KdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiTHnnbJQzKGOnbHzzJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByMkOg{txONg>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6OEK3PEc,Ojh4OEiyO\|g9N2F-
Light2	MkfBSpVv[3Srb36gZZN{[Xl?		NILjUpU1QCCqcoO=	NYXlbmRLUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDMbYdpfDJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGdtcS2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlAxOjR4IN88UU4>	MoXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{m3NVQoRjJ7N{O5O\|E1RC:jPh?=
HEPM	MYHGeY5kfGmxbjDhd5NigQ>?			MVLJcohq[mm2aX;uJI9nKFOKSDDpckBpfW2jbjDISXBOKGOnbHzzJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmQSDC9JFAvODB{ODFOwG0v	NEX4cWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUexOlI6Pid-MUm3NVYzQTZ:L3G+
Shh Light2	MkTmSpVv[3Srb36gZZN{[Xl?			NYHFc4JPUW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqIFzp[4h1OiClZXzsd{BjgSCJTFmtdoV{eG:wc3n2[UBncXKnZnz5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMECzJO69VS5?	NUHJ[GtzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFkxQDBpPkG5N\|A6ODhyPD;hQi=>
HEPM	MXnGeY5kfGmxbjDhd5NigQ>?			MljZTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gbJVu[W5iSFXQUUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icnXj[ZB1d3JvbXXkbYF1\WRiR3zpNUBuWk6DIHX4dJJme3Orb36gZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiSV7IJF0hOC5yMEOg{txONg>?	M3rPflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1O\|QyLz5{MEi3OVc1OTxxYU6=
C3H10T1/2	MVXGeY5kfGmxbjDhd5NigQ>?		MmrkNlAhcHK\|	NHr2T\|BKdmirYnn0bY9vKG:oIGPtc{BqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgeZNqdmdiaIXtZY4hemWlb33ibY5idnRiU1jIJIF{e2W\|c3XkJIF{KGWoZnXjeEBwdiCVTV:vV2hJKHS{YX7zbYVvfCC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCjZoTldkAzOCCqcoOgZpkhT2yrLXz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFnDOVAhRSByLkCwOUDPxE1w	NYf4bXlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA1OzZpPkK0PVAxPDN4PD;hQi=>
NIH/3T3	NFHqRXRHfW6ldHnvckBie3OjeR?=		M3LiW\|I1KGi{cx?=	NH7meIJKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgNlQhcHK\|IHL5JGdtcS2mdXHsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC1JO69VS5?	M3nmWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVkyLz5{N{ixNFU6OTxxYU6=
NIH3T3	M{HiPWZ2dmO2aX;uJIF{e2G7		M2XqXFQ5KGi{cx?=	M4W4dWlvcGmkaYTpc44hd2Zic33vMY1m\GmjdHXkJIhm\GenaH;nJJNq\26jbHnu[{Bx[XSqd3H5JIlvKG2xdYPlJG5KUDOWMzDj[YxteyCneIDy[ZN{cW6pIFfSSU1NfWNicnXwc5J1\XJiZ3Xu[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNCTy2rbnT1Z4VlKEeURT3MeYMhemWyb4L0[ZIh[WO2aY\peJkh[W[2ZYKgOFghcHK\|IHL5JIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODB4IN88UU4>	MnTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OUm0PFMoRjJ7NEm5OFg{RC:jPh?=
Shh-light2	NWXqWmNFTnWwY4Tpc44h[XO\|YYm=			M3Tnd2lvcGmkaYTpc44hd2ZiU33vMY1m\GmjdHXkJGhpKHOrZ37hcIlv\yCrbjDoeY1idiCVaHitcIlocHR{IHPlcIx{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5IN88UU4>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
HEK293	MXTGeY5kfGmxbjDhd5NigQ>?		NG\Fc5UzKGi{cx?=	MVTEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWyjYnXscIVlKGO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHluIFnDOVAhRSByLkCwO{DPxE1w	M4C1O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
NIH3T3	NIXLdHJHfW6ldHnvckBie3OjeR?=			MYrJcohq[mm2aX;uJI9nKGinZHflbI9oKHKnY3XweI9zKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSEPUN{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIFfsbU1z\XCxcoTldkBo\W6nIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC3NVch\|ryPLh?=	NWezb25ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlM4PjVpPkK0PVI{PzZ3PD;hQi=>
NIH/3T3	NX;Lc\|h5TnWwY4Tpc44h[XO\|YYm=		NIqwbow1QCCqcoO=	NWLt[JFEUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBUd26rYzDo[YRo\WixZz3pcoR2[2WmIFfsbUBtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBFfWGuLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5MUeg{txONg>?	M1nyfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS5OFk1Lz5\|MEK0PVQ6PDxxYU6=
NIH3T3	MVfGeY5kfGmxbjDhd5NigQ>?		NFn6XYU1QCCqcoO=	NUjXcVJxUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyuaX7nJIlvKG2xdYPlJG5KUDOWMzDj[YxteyC\|dHHicJkhfHKjboPm[YN1\WRid3n0bEBIdGlvbIXjbYZmemG\|ZTDjc45{fHK3Y4SgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwO\|Ih\|ryPLh?=	Mnr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6MkexN\|YoRjJ4OEK3NVM3RC:jPh?=
NIH3T3	M3LiN2Z2dmO2aX;uJIF{e2G7		NVvHWpZiPDhiaILz	Mn\4TY5pcWKrdHnvckBw\iCVb37pZ{1qdmS3Y3XkJIhm\GenaH;nJJNq\26jbHzpcochcW5ibX;1d4UhVkmKM2SzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygTWM2OCB;IECuNFA4OiEQvF2u	NUX4bXV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NlA2PTRpPkK2PFIxPTV2PD;hQi=>
NIH3T3	MUjGeY5kfGmxbjDhd5NigQ>?		MonpOFghcHK\|	NHzTSo5KdmirYnn0bY9vKG:oIGPITEB{cWewYXzpcocheGG2aIfhfUBqdiCvb4Xz[UBPUUh\|VEOgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDJR\|UxKD1iMD6wNFczKM7:TT6=	Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{[zPVYoRjJ2MUe2N\|k3RC:jPh?=
NIH/3T3	NVH2cnM6TnWwY4Tpc44h[XO\|YYm=		MmjCOFghcHK\|	NEe1TGFKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGdtcS2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlAxPzJizszNMi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkKwN{c,OjR2OE[yNFM9N2F-
NIH/3T3	NUH0NJBGTnWwY4Tpc44h[XO\|YYm=			M37QZ2lvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM\|NVOyClZXzsd{BjgSCJbHmxMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC3NkDPxE1w	NX3BXYE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFU4ODRpPkK0OFA2PzB2PD;hQi=>
NIH/3T3	NYDyRmM3TnWwY4Tpc44h[XO\|YYm=			NYTSToFMUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGOjcoL5bY5oKHO2YXLsfUB1emGwc3\lZ5Rm\CCJbHmtdoVxd3K2ZYKgZ49ve3S{dXP0JIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUCgQUAxNjByN{Kg{txONg>?	NUKydZI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OFIyODFpPkK4OlQzOTBzPD;hQi=>
C3H10T1/2	NX;Ue241TnWwY4Tpc44h[XO\|YYm=		NHzsd\|U3KGi{cx?=	MoK2TY5pcWKrdHnvckBw\iCVQVetbY5lfWOnZDDkbYZn\XKnboTpZZRqd25ib3[gcY92e2VibXXz[Y5kcHmvYXygdIx2emmyb4TlcpQhSzOKMUDUNU8zKGOnbHzzJJRwKGGua3HsbY5mKHCqb4PwbIF1[XOnIIDvd4l1cX[nIH;ld4Vw[myjc4TzJIFnfGW{IE[gbJJ{NCCLQ{WwJF0hOC5yMUGg{txONg>?	M3i2d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
HCC827	M{L6WGZ2dmO2aX;uJIF{e2G7			MUfEbZNxdGGlZX3lcpQhd2ZiW{PIYU1kgWOub4DhcYlv\SCocn;tJHNOVyCYNEC0UUBufXSjboSgbY4h\2WoaYTpcoljKHKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3mgQUAxNjBzMkKg{txONg>?	MkHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OEexOVYoRjJ6N{i3NVU3RC:jPh?=
C3H10T1/2	M3rjTGZ2dmO2aX;uJIF{e2G7			MUfJcohq[mm2aX;uJI9nKFOKSDDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYomgS4xqNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFE{KM7:TT6=	NXPybmFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NVYzQTZpPkG5O\|E3Ojl4PD;hQi=>
S12	NHPqXGtHfW6ldHnvckBie3OjeR?=			NVLHb5J1UW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgV\|EzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDy[YNmeHSxcj3t[YRq[XSnZDDHcIkyKG2UTlGg[ZhxemW\|c3nvckBjgSC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJUmghRSByLkCxN{DPxE1w	NUHPOldbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|U4PDFpPkKwPFc2PzRzPD;hQi=>
TM3	NUPkR2R{TnWwY4Tpc44h[XO\|YYm=		NYXPNFZLPDhiaILz	MUnJcohq[mm2aX;uJI9nKEiqIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIGTNN{Bk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIHflcoUh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxKD1iMD6wNVMh\|ryPLh?=	M4P6RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUe2NlE2Lz5{Nkm3OlIyPTxxYU6=
NIH/3T3	NF;s[mhHfW6ldHnvckBie3OjeR?=			MW\Jcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhW22xIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCJbHmgcXJPSSCneIDy[ZN{cW:wIHL5JHJVNVCFUjDt[ZRpd2RuIFnDOVAhRSByLkCxOFQh\|ryPLh?=	M2\wclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVkyLz5{N{ixNFU6OTxxYU6=
S12	NVPOSJBGTnWwY4Tpc44h[XO\|YYm=		NEezd\|E1QCCqcoO=	NX3qN\|NmUW6qaXLpeIlwdiCxZjDoeY1idiCVSFigdIF1cHejeTDpckBud3W\|ZTDTNVIh[2WubIOgZZN{\XO\|ZXSgZZMhT0yLLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNVUh\|ryPLh?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR\|OEWyO{c,OjF2M{i1Nlc9N2F-
NIH/3T3	M1LQbmZ2dmO2aX;uJIF{e2G7			NWDyVVZNUW6qaXLpeIlwdiCxZjDTUW8hcW5ibX;1d4UhVkmKL{PUN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPBS{1qdmS3Y3XkJIhm\GenaH;nMY1m\GmjdHXkJIx2dWmwZYPj[Y5k\SC\|aXfuZYxqdmdiYomgS3JGNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFE3KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUWwNEc,OjZzMUm1NFA9N2F-
U2OS	MUjGeY5kfGmxbjDhd5NigQ>?		Ml\3NkBpenN?	NX7EeZdnTGm\|cHzhZ4Vu\W62IH;mJHs{UF2leXPsc5BidWmwZTDmdo9uKHerbHSgeJlx\SCVbX:g[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4khRSByLkCxOlIh\|ryPLh?=	M4nUUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[zOVIzLz5{M{C2N\|UzOjxxYU6=
NIH3T3	NWjxPId[TnWwY4Tpc44h[XO\|YYm=		Mn[xN\|AhcHK\|	MXLJcohq[mm2aX;uJI9nKFOvbzDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBPUUh\|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVbX:gZYdwdmm\|dDDTRWcucW6mdXPl[EBIWkViYXP0bZZifGmxbjDh[pRmeiB\|MDDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOjNizszNMi=>	NWS5TnBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODdpPkK0O\|I3QDB5PD;hQi=>
medulloblastoma cell	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVOzOkBpenN?	NVG5OY1XSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBRfGOqKz:tJIFv\CCyNUOtM{0hdW:3c3WgcYVlfWyub3LsZZN1d22jIHPlcIx{KGGodHXyJFM3KGi{czDifUBDemS3IHnuZ49zeG:{YYTpc44h[XO\|YYmsJGlEPTBiPTCwMlA{ODRizszNMi=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6OEK3PEc,Ojh4OEiyO\|g9N2F-
Shh Light2	NVmwW3l2TnWwY4Tpc44h[XO\|YYm=			M1HkdWFvfGGpb37pd5Qh[WO2aY\peJkh[XRic33vc5Rp\W6nZDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDTbIghVGmpaISyJINmdGy\|IHPvMYV5eHKnc4PpcochT2yrLXTldIVv\GWwdDDy[ZBwenSncjDn[Y5mKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhUGhic3nncoFtcW6pIHL5JIR2[WxibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOzNizszNMi=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
Light2	MWfGeY5kfGmxbjDhd5NigQ>?			MmG5TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCOaXfoeFIh[2WubIOgbY4hW2iqIHPvcoRqfGmxbnXkJI1m\Gm3bTDifUBIdGlvbIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOzlizszNMi=>	MmThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
Shh Light2	MoHwSpVv[3Srb36gZZN{[Xl?			NI\PXJhKdmirYnn0bY9vKG:oIGPtc{1u\WSrYYTl[EBJcCC\|aXfuZYxtcW6pIIDheIh4[XliaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCkeTDHcIkudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wN\|kzKM7:TT6=	M1W2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{O2NFY{Lz5{N{ezOlA3OzxxYU6=
ASZ001	MnzjSpVv[3Srb36gZZN{[Xl?		NHjiRmo1QCCqcoO=	NXu4S4ZqUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgRXNbODBzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIFfsbVEhdVKQQTDlfJBz\XO\|aX;uJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNuIFnDOVAhRSByLkC0JO69VS5?	MoCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
NIH/3T3	MYTGeY5kfGmxbjDhd5NigQ>?		M4HZS\|Q5KGi{cx?=	M{TWXGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiU33vJJJm[2WydH;yJIlvKG2xdYPlJG5KUC9\|VEOgZ4VtdHNiaHHyZo9zcW6pIFfSSU1NfWNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVQVetbY5lfWOnZDDIbEB{cWewYXzpcocheGG2aIfhfUBxemWrbnP1ZoF1\WRid3n0bEBk\WyuczDmc4xtd3enZDDifUBUSUdiYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFQ3KM7:TT6=	NWP1c3RURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVczPzVpPkK5PFU4Ojd3PD;hQi=>
Light2	MV3GeY5kfGmxbjDhd5NigQ>?		MWSzNEBpenN?	NEXJPIpKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIFzp[4h1OiClZXzsd{BqdiCVaHigZ49v\Gm2aX;u[YQhdWWmaYXtJIFnfGW{IEOwJIhzeyCkeTDHcIkuWmWwaXzsZUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkC1JO69VS5?	NYLCfoM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVkzPTdpPkOwNFk6OjV5PD;hQi=>
C3H10T1/2	M1zQNGZ2dmO2aX;uJIF{e2G7		NULmfYJzPiCmYYnz	Mn7vTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigS2vZXTpZZRm\CCmaX\m[ZJmdnSrYYTpc44hd2ZibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIGPBS{1qdmS3Y3XkJGFNWCCjY4Tpeol1gSCjZoTldkA3KGSjeYOgZpkh[2inbXnseY1qdmW\|Y3XuZ4Uu[mG\|ZXSgZZN{[XluIFnDOVAhRSByLkC1JO69VS5?	M{Lv[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm5NlU4Lz5\|MEC5PVI2PzxxYU6=
DaOY	M1HyVWZ2dmO2aX;uJIF{e2G7		NGLTNZM1QCCqcoO=	NIPpTlVKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBpfW2jbjDEZW9[KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDR6IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjB6NjFOwG0v	MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
C3H10T1/2	MVnGeY5kfGmxbjDhd5NigQ>?		NXz6TVVbOSCqch?=	M{KwNGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBxfXKvb4LwbIFucW6nLXnu[JVk\WRiaX7jdoVie2ViaX6gZYxs[WyrbnWgdIhwe3CqYYThd4UhdGW4ZXygeZNqdmdiQ1TQMZN1[XJiYYOgd5Vje3S{YYTlJJBz\XS{ZXH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nlicIXycY9zeGijbXnu[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC1JIRigSxiSVO1NEA:KDBwMUSg{txONg>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl2N{mzPUc,Ojh7NEe5N\|k9N2F-
M210B4	M3foOGZ2dmO2aX;uJIF{e2G7		MWqyOEBpenN?	Mn;OTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViTUKxNGI1KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKFC2Y3igcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjF2IN88UU4>	MlH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
M210B4	MYPGeY5kfGmxbjDhd5NigQ>?		M1XFTVI1KGi{cx?=	M{L1VGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC5{IN88UU4>	M13Y[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
Shh Light2	NIS0TnpHfW6ldHnvckBie3OjeR?=		MmnENUBpeg>?	MWPJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCVaHigUIlocHR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBxfXKvb4LwbIFucW6nLXnu[JVk\WRiR3zpJI1m\GmjdHXkJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDwdoV1emWjdHXkJIZweiBzIHjyJIZwdGyxd3XkJIJ6KHC3cn3vdpBp[W2rbnWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvQThizszNMi=>	NX;aS5VLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OFc6OzlpPkK4PVQ4QTN7PD;hQi=>
NIH/3T3	NIPQZmdHfW6ldHnvckBie3OjeR?=			NVnxbHFUUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGijcnLvdolv\yCVbX:gSFQ4P0hibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBIdGlibWLORUBmgHC{ZYPzbY9vKGK7IGLUMXBEWiCvZYToc4QtKEmFNUCgQUAyNjF7NjFOwG0v	NEnzWoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixNFU6OSd-Mke4NVA2QTF:L3G+
S12	MnHNSpVv[3Srb36gZZN{[Xl?		NF74R3U1QCCqcoO=	MkPlTY5pcWKrdHnvckBw\iCqdX3hckBUUEhicHH0bJdigSCrbjDtc5V{\SCVMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgS2xKNW2nZHnheIVlKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJFAvPSCvZz;tUEBpfW2jbjDhcJBp[S1zLXHjbYQh\2y7Y3;wdo91\WmwLDDJR\|UxKD1iMT63OUDPxE1w	NF\5RYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSzPFUzPyd-MkG0N\|g2Ojd:L3G+
Calu6	M3q0OGZ2dmO2aX;uJIF{e2G7		MonXOEBpenN?	NW\SWpo6WGyjc33hJINwdmOnboTyZZRqd25iaX6gbJVu[W5iQ3HseVYh[2WubIOgfIVvd2e{YX\0[YQhcW5iboXk[UBud3W\|ZTDheEA4PSCvZz;r[{wheG9iYnnkJI1m[XO3cnXkJIFnfGW{IESgbJJ{KHCxc4Sg[olnfGhiZH;z[UwhS3BiPTCyN{DPxE1w	Mn\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MU[yPVYoRjF7N{G2Nlk3RC:jPh?=
Calu-6	NIr4b5RHfW6ldHnvckBie3OjeR?=			MlfIVIxie22jIHPvcoNmdnS{YYTpc44hcW5iQ3HseU03KGOnbHzzJJhmdm:pcnHmeIVlKG63ZHWgcY92e2ViUFuvVGQhdW:mZXygZZQhPzVibXevb4ctKHCxIHLp[EBnd3JiNTDkZZl{KG2nYYP1doVlKDRiaILzJJBwe3RibHHzeEBld3OnIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;sMEBEeCB;IEKzJO69VS5?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUe0NUc,OjB6N{W3OFE9N2F-
T47D	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		MV[3NkBpenN?	MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0NU4{PCEQvF2u	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEe0NlkoRjJ7MUC3OFI6RC:jPh?=
LS180	M4q3SWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGrkdXA4OiCqcoO=	NFXCbpVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzTNVgxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\S2EIHHzd4F6NCCLQ{WwJF0hPDVizszNMi=>	MkfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUmyOVcoRjNyMEm5NlU4RC:jPh?=
LS174T	NETqeI5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYe3NkBpenN?	MmDtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOU{G3OHQh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0OU45OSEQvF2u	MnnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6MkC1OVQoRjJ4OEKwOVU1RC:jPh?=
BxPC3	Mk\CRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MX:3NkBpenN?	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEK6UFOzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEeuPVUh\|ryPLh?=	NWfyNIo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NlA2PTRpPkK2PFIxPTV2PD;hQi=>
medulloblastoma cell	M3ftWmFvfGm2dX3vdkBie3OjeR?=			NFfjNVZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDt[YR2dGyxYnzhd5RwdWFiY3XscJMhgGWwb3fyZYZ1\WRiaX6gVJRkcCBtLz2gcY92e2ViYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hfHWvb4Kgeo9tfW2nIHH0JFEzNjVibXevb4ctKHCxIHLp[E4>	MoTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MU[yPVYoRjF7N{G2Nlk3RC:jPh?=
S12	NHLIc4ZHfW6ldHnvckBie3OjeR?=		NWfvfoFuPDhiaILz	NX;jU5hnUW6qaXLpeIlwdiCxZjDoeY1idiCVSFigdIF1cHejeTDpckBud3W\|ZTDTNVIh[2WubIOgZZN{\XO\|ZXSgZZMhT0yLLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDFibXevcWwhcHWvYX6gZYxxcGFvMT3hZ4llKGeueXPvdJJwfGWrbj6=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR\|OEWyO{c,OjF2M{i1Nlc9N2F-
Shh Light2	MWHGeY5kfGmxbjDhd5NigQ>?	MlS4NE4yKHWP	MlvYN\|YhcHK\|	M1;1bGlvcGmkaYTpc44hd2ZiU33vMY1m\GmjdHXkJGhpKHOrZ37hcIxqdmdicHH0bJdigSCrbjDtc5V{\SCVaHigUIlocHR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKEeuaUGtcXJPSSCneIDy[ZN{cW:wIHH0JFAvOSC3TTDt[YF{fXKnZDDh[pRmeiB\|NjDodpMh[nliUmStdXBEWiCjbnHsfZNqey5?	M4TndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{O2NFY{Lz5{N{ezOlA3OzxxYU6=
SW1353	MnvjRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NUmyTXRKOTBidV2=	MojJOFghcHK\|	NYmwWW9VSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW\|E{PTNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhfU1iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigS5?	NGPYTY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
DaOY	M1fm[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7	M1foWlExKHWP	NHzC[5I1QCCqcoO=	NHfDWGVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFThU3kh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[XRiMUCgeW0h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfU4>	NW[ySmNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVE1PTlpPkK0OFkyPDV7PD;hQi=>
A549	Mm\JRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	M2ficFExKHWP	NXjxb2JZPDhiaILz	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZZQhOTBidV2gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeT6=	M{fBUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEmxOFU6Lz5{NES5NVQ2QTxxYU6=
HCT116	M3HoUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NFrFV2oyOCC3TR?=	NYfDSIRnPDhiaILz	Mne0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[XRiMUCgeW0h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfU4>	NHLkZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
NIH/3T3	NYrVR21JTnWwY4Tpc44h[XO\|YYm=	MnnXNVAhfU1?		NVjFXJRQUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCjc4Pld5Nm\CCjczDkc5dvKHKnZ4XsZZRqd25ib3[gcXBVS0hzIH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VS5?	NU\iSVM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVE1PTlpPkK0OFkyPDV7PD;hQi=>
MSC	M4LuV2Z2dmO2aX;uJIF{e2G7	M4iyNlIxKHSxIEiwJJVO		NHvrO21KdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDNV2Mh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5bjDy[Yd2dGG2aX;uJI9nKGGua3HsbY5mKHCqb4PwbIF1[XOnIHH0JFIxKHSxIEiwJJVONg>?	NGq4[5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
SK-N-MC	MV7xTHRUKGG\|c3H5			MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucz6=	NIDjWos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	M2DibJFJXFNiYYPzZZk>			MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzzMi=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NIH3T3-Luc	MonuSpVv[3Srb36gZZN{[Xl?	M3rxWFEhfU1?	MV20PEBpenN?	NGHWZZZKdmirYnn0bY9vKG:oIIPtc{1u\WSrYYTl[EBp\WSpZXjv[{B{cWewYXzpcocheGG2aIfhfUBqdiCvb4Xz[UBPUUh\|VEOtUJVkKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaTDtVm5CKGW6cILld5Nqd25iYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhemWjbD30bY1mKFCFUjDhcoFtgXOrcz6=	NVOzRWdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDNpPkK5OFk6PDh\|PD;hQi=>
C3H10T1/2	MmKxSpVv[3Srb36gZZN{[Xl?		MUKyOEBpenN?	MmnjTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigS2vZXTpZZRm\CCJTFmxJI1TVkFiZYjwdoV{e2mxbjDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCoNXItO2GULETTMFdiWilvN3GtcYV1cHmuLUGtLEhTMS14LX3leIh6dGincIThck0zNXmuKX;jeIFpgWS{bz2xTE1qdmSnbj20MZltKDNvaInkdo95gWKnborvZZRmNg>?	NXzPZlloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3N\|A6QDRpPkK0O\|MxQTh2PD;hQi=>
C3H10T1/2	Ml3JSpVv[3Srb36gZZN{[Xl?		NVzMTZhROjRiaILz	M4fVcmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XlvbXXkbYF1\WRiR1zJNUBuWk6DIHX4dJJme3Orb36gbY4hdW:3c3WgR\|NJOTCWMT:yJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMhcW5icILld4Vv[2Vib3[gWmQ{Ng>?	M3v2R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{OwPVg1Lz5{NEezNFk5PDxxYU6=
NIH/3T3	NGnoXY9HfW6ldHnvckBie3OjeR?=	NXLNc40yOTByIH7N	NXnRUHBtOzZiaILz	MnG1TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKFOqaD3pcoR2[2WmIFfsbVEhdVKQQTDlfJBz\XO\|aX;uJIxmfmWuczDheEAyODBibl2gZYZ1\XJiM{[gbJJ{KGK7IGLUMZFRS1JiYX7hcJl{cXNw	NXrX[ZlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4O\|M{ODNpPkK4PFc{OzB\|PD;hQi=>
C3H10T1/2	NXvIeIpxTnWwY4Tpc44h[XO\|YYm=	NVHKeIlFOTByIH7N	NUnjVZh1OzZiaILz	Mn7rTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCFM1ixNHQyNzJiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiU3joMYlv\HWlZXSgS4xqOSCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJIF1KDFyMDDuUUBi\nSncjCzOkBpenNiYomgVnQueVCFUjDhcoFtgXOrcz6=	M1jsclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN\|A{Lz5{OEi3N\|MxOzxxYU6=
NIH/3T3	M2HwT2Z2dmO2aX;uJIF{e2G7	MofGNVAxKG6P	MkPWN\|YhcHK\|	NFXpXHRKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiU3joMYlv\HWlZXSgdJRkcDFibWLORUBmgHC{ZYPzbY9vKGyndnXsd{BifCBzMECgcm0h[W[2ZYKgN\|YhcHK\|IHL5JHJVNXGSQ2KgZY5idHm\|aYOu	M4iwUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN\|A{Lz5{OEi3N\|MxOzxxYU6=
C3H10T1/2	MoGxSpVv[3Srb36gZZN{[Xl?	NEH3fWIyODBibl2=	NFG0b3c{PiCqcoO=	NWLuXYQ5UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gV4hpNWmwZIXj[YQheHSlaEGgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCjdDCxNFAhdk1iYX\0[ZIhOzZiaILzJIJ6KFKWLYHQR3Ih[W6jbInzbZMv	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
medulloblastoma cell	NIDNbodCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MUH1dEB1dyB\|MDD1US=>	NXrLTm1TPzJiaILz	NUjVd5VUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDQeINpMy9vIIC1N{0wNSCvZXT1cIxw[myjc4TvcYEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjD1dEB1dyB\|MDD1UUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5Mi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
medulloblastoma cell	M{noU2Fxd3C2b4Ppd{Bie3OjeR?=			NInEb4VKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJI1wfXOnIGD0Z4gsNy1icEWzMU8uKG2nZIXscI9jdGG\|dH;tZUBk\WyuczDpcZBt[W62ZXSgbY4h[XSqeX3pZ{BvfWSnIH3veZNmKGG2IEGyMlUhdWdxa3esJIlxKGKrZDDmc5IhOTViY3;ud4VkfXSrdnWg[IF6eyCkeTDUWW5GVCCjc4PhfU4>	NIjkc5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi3N\|MxOyd-Mki4O\|M{ODN:L3G+
NIH/3T3	NGTPXVhHfW6ldHnvckBie3OjeR?=			M4HtS2lvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE8{XDNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBp\WSpZXjv[{1qdmS3Y3XkJGdtcS1{IHHjZ5VufWyjdHnvckBifCC2aYCgc4YheHKrbXHyfUBkcWyrYTDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGOxbn\vZ4FtKG2rY4Lvd4NweGmlIHHuZYx6e2m\|Lh?=	NF6wWIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixNFU6OSd-Mke4NVA2QTF:L3G+
NIH/3T3	NE\adWZHfW6ldHnvckBie3OjeR?=			MkHxTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbIVl\2Wqb3etbY5lfWOnZDDTcY8uTUeIUDDjbYxq[XK7IITyZY5{dG:lYYTpc44h[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDjc45nd2OjbDDtbYNzd3Olb4DpZ{BidmGueYPpd{4>	MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PVEoRjJ5OEGwOVkyRC:jPh?=
medulloblastoma cell	NInZUlNCdnSrLYT1cY9zKGG\|c3H5			NUXFbow4SW62aT30eY1weiCjY4Tpeol1gSCjZ3HpcpN1KG2xdYPlJHB1[2htLz2gdFU{NS9vIH3l[JVtdG:kbHHzeI9u[SClZXzsd{BqdXCuYX70[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFIxKG2pL3vnMEBxdyCjZH3pcol{fGW{ZXSgeJdq[2ViZHHpcJkhfmmjIHfheoFo\SCvZXHzeZJm\CCndnXyfUBwfGincjDkZZkh\HW{aX7nJINwdXCxdX7kJIRwe2mwZz6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|OUexOEc,Ojl5M{m3NVQ9N2F-
C3H10T1/2	MorzSpVv[3Srb36gZZN{[Xl?	M1rENFQvOSC2bzCxNFAxKG6P		NGjRWWdCdGyxc4TldolkKGmwaHnibZRqd25ib3[gV41wKGmwIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJB2em2xcoDoZY1qdmVvaX7keYNm\CCJbHmxJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDheEA1NjFidH:gNVAxOCCwTTDifUByWEO{IHHuZYx6e2m\|Lh?=	NFHsdG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3OFU1OSd-MkOwO\|Q2PDF:L3G+
C3H10T1/2	MnHqSpVv[3Srb36gZZN{[Xl?	NWPYfYJ6PC5zIITvJFExODBibl2=		NXnyeWVLS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBUdW9iaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhW0GJLXnu[JVk\WRiR3zpNUB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZZQhPC5zIITvJFExODBibl2gZpkheVCFUjDhcoFtgXOrcz6=	NUDLUFgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwO\|Q2PDFpPkKzNFc1PTRzPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα; PubMed: 22087285 PLoS One Pancreatic CSCs were treated with GDC-0449 (0, 1, 5 and 10 µM) for 48 h. The expression of Fas, DR4/TRAIL-R1, DR5/TRAIL-R2, PARP cleavage, Bcl-2, and Caspase-3 by the Western blot analysis. β-Actin was used as a loading control. p-GSK3β / GSK3β / p-Akt / Akt / Gli1; PubMed: 27143997 Oxid Med Cell Longev Cells were pretreated with or without 30 μM GDC-0449 for 2 h before TMT treatment. After incubation with 3.75 μM TMT for another 24 h, the expression levels of proteins were determined through Western blot analysis. Gli1 / SOX2 / OCT4; PubMed: 26418365 Stem Cells The activation of Hedgehog pathways and CSC markers were tested by immunoblotting analysis in Hs578T and BT549 cells. β‐Actin was used as a loading control. p53 / Cyclin D1 / p21; PubMed: 28195165 Sci Rep GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies. Bcl-2 / Bax; PubMed: 28195165 Sci Rep GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies.	22087285 27143997 26418365 28195165
Immunofluorescence	Gli1 / Gli2; PubMed: 22087285 PLoS One GDC-0449 inhibits expression of Gli1 and Gli2 in human pancreatic CSCs. The cells were seeded on fibronectin-coated coverslips and treated with GDC-0449 (10 µM) for 48 h. Subsequently, cells were fixed with 4% paraformaldehyde, blocked in 10% normal goat serum and stained with Gli1 and Gli2 primary antibodies (1∶100) for 16 h at 4°C and washed with PBS. Afterwards, cells were incubated with fluorescently labeled secondary antibody (1∶200) along with DAPI (1 mg/ml) for 1 h at room temperature and cells were mounted and visualized under a fluorescent microscope. For better visuality, the color of DAPI was changed from blue to red.	22087285
Growth inhibition assay	Cell viability; PubMed: 29042665 Sci Rep GDC-0449 improves the anti-proliferation activity in NIH-3T3 cells but not in BxPC-3, Panc-1, MIAPaca-2 and SW1990 cells when cultured alone. The cytotoxicities of GDC-0449, Dox or Dox with GDC-0449 (5 μM or 10 μM) were measured by performing a 48-h MTT assay in BxPC-3 (A), Panc-1 (B), MIAPaca-2 (C), SW1990 (D) and NIH-3T3 (E) cells. Apoptosis rate was detected by flow cytometry (Annexin V staining) analysis after treatment with Dox (200 nM) with or without GDC-0449 for 24 h (F). Data are presented as the mean ± SD. P < 0.05, *P < 0.01.	29042665

体内研究

GDC-0449已经用于治疗动物模型的成髓细胞瘤。^[2] GDC-0449 抑制原代胰腺移植瘤生长，但是不抑制细胞增殖。GDC-0449按25 mg/kg 以上剂量口服给药髓母细胞瘤Ptch(+/-)异体移植物模型，引起细胞衰退，按92 mg/kg剂量处理两种配位体依赖的结肠直肠癌模型D5123和1040830，每天处理两次，抑制肿瘤生长。分析Hh通路活性和 PK/PD 模型显示GDC-0449抑制 Gli1，IC50值与GDC-0449作用于髓母细胞瘤和D5123模型的IC50值差不多(分别为0.165 μM ±11.5% 和0.267 μM ±4.83%)。^[4]

细胞实验：^[2]	- 合并 Cell lines: MDCKII细胞 Concentrations: 20 μM Incubation Time: 2小时 Method: MDCKII细胞按每孔3x10⁵密度接种在24孔板中。培养液包含不同药物，实验组为50 µM VP,50 µM吲哚美辛,或者20 µM GDC-0449溶解在DMSO中，对照组只含有DMSO。然后加入非荧光的钙黄绿素-AM，最终浓度达到1.0 µM。然后在37^oC温育2小时。细胞用含Ca²⁺,Mg²⁺的Hank's平衡盐溶液buffer冲洗2次，然后震荡1小时溶解在含0.01% Triton X-100的磷酸缓冲液中，然后放在4^oC下过夜。溶解的物质然后转移到96孔板上，钙黄绿素引起的荧光信号用分光光度法定量。所有的实验操作需在暗中进行，所有的读数用平均值±SEM表示。 (Only for Reference)
动物实验：^[4]	- 合并 Animal Models: Ptch(+/-)异体移植物模型 Dosages: 25 mg/kg,92 mg/kg Administration: 口服 (Only for Reference)

参考文献

[4] Wong H, et al. Clin Cancer Res. 2011, 17(14), 4682-4692.

- 合并

溶解度 (25°C)

体外	DMSO	84 mg/mL (199.38 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	12.5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vismodegib (GDC-0449) SDF

分子量	421.3
化学式	C₁₉H₁₄Cl₂N₂O₃S
CAS号	879085-55-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03610022	Recruiting	Drug: Treatment with vismodegib	Metastatic Basal Cell Carcinoma\|Locally Advanced Basal Cell Carcinoma	University Hospital Bordeaux	September 3 2018	Phase 4
NCT03035188	Unknown status	Drug: Vismodegib	Basal Cell Carcinoma	SRH Wald-Klinikum Gera GmbH	January 2017	Phase 2
NCT02371967	Completed	Drug: Vismodegib	Basal Cell Carcinoma	Hoffmann-La Roche	April 8 2015	--
NCT02667574	Active not recruiting	Drug: ERIVEDGE	Basal Cell Carcinoma	University Hospital Lille\|Hoffmann-La Roche	November 18 2014	Phase 2
NCT02067104	Terminated	Drug: Vismodegib\|Drug: Placebo	Basal Cell Carcinomas	University of Arizona	February 17 2014	Phase 2
NCT01774253	Terminated	Drug: Vismodegib	Pontine Glioma	Giselle SaulnierSholler\|Phoenix Children''s Hospital\|Atrium Health	May 2013	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

选择性强的Smoothened抑制剂

PF-5274857 : Smoothened-selective, IC50=5.8 nM.
用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Vismodegib (GDC-0449)

客户使用Selleck生产的Vismodegib (GDC-0449)发表文献144篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vismodegib (GDC-0449) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品